Faculty & Scientific Staff
Carla Greenbaum, MD
Dr. Greenbaum is a member of BRI’s Center for Interventional Immunology and a leader in efforts to prevent and delay type 1 diabetes (T1D) and improve outcomes for people living with the disease. She earned her medical degree from Brown University and completed her endocrinology fellowship at the University of Washington.
As a clinical investigator, Dr. Greenbaum focuses on understanding the causes and progression of T1D and evaluating interventions designed to preserve insulin-producing beta cells and alter the course of disease. Her research spans clinical trials, biomarker discovery, and the development of strategies to identify individuals at risk for T1D before symptoms appear.
Dr. Greenbaum previously served as chair of Type 1 Diabetes TrialNet, a National Institutes of Health sponsored international consortium dedicated to testing disease-modifying therapies for T1D, and currently serves as co-principal investigator of the TrialNet Clinical Hub. She has led and contributed to numerous academic- and industry-sponsored clinical trials aimed at preventing, delaying or treating T1D as well as clinical research studies exploring disease mechanisms.
Her work continues to advance biomarkers, clinical trial approaches, and therapeutic strategies that improve outcomes for people at risk for or living with T1D and other autoimmune diseases.
Featured Publications
-
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
N Engl J MedHerold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ, Type 1 Diabetes TrialNet Study Group. -
Characterising the age-dependent effects of risk factors on type 1 diabetes progression.
DiabetologiaSo M, O'Rourke C, Ylescupidez A, Bahnson HT, Steck AK, Wentworth JM, Bruggeman BS, Lord S, Greenbaum CJ, Speake C -
Risk Modeling to Reduce Monitoring of an Autoantibody-Positive Population to Prevent DKA at Type 1 Diabetes Diagnosis.
J Clin Endocrinol MetabO'Rourke C, Ylescupidez A, Bahnson HT, Bender C, Speake C, Lord S, Greenbaum CJ -
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.
Diabetes CareRussell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, Gottlieb PA, Greenbaum CJ, Haller MJ, Krischer JP, Libman IM, Linsley PS, Long SA, Lord SM, Moore DJ, Moore WV, Moran AM, Muir AB, Raskin P, Skyler JS, Wentworth JM, Wherrett DK, Wilson DM, Ziegler AG, Herold KC, Type 1 Diabetes TrialNet Study Group -
A Key to T1D Prevention: Screening and Monitoring Relatives as Part of Clinical Care.
DiabetesGreenbaum CJ
